News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Amicus Therapeutics, Inc. (FOLD) to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy for Fabry Disease


6/17/2013 8:59:17 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., June 17, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced that John F. Crowley, Chairman and Chief Executive Officer, will host a conference call at 8:00 a.m. ET this morning. Mr. Crowley will highlight the regulatory strategy for migalastat HCl monotherapy for Fabry disease following a recent Type C meeting with the U.S. Food and Drug Administration (FDA).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES